Skip to main content Accessibility help
  • Print publication year: 2015
  • Online publication date: April 2015

Chapter 25 - Human papillomaviruses

from Section 3 - Gynecological infectious disease

Related content

Powered by UNSILO


1. HoGY, BiermanR, BeardsleyL, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423–428.
2. CastellsagueX, MunozN. Cofactors in human papillomavirus carcinogenesis – role of parity, oral contraceptives, and tobacco smoking. JNCI Monogr 2003;20–28.
3. CastlePE, GiulianoAR. Genital tract infections, cervical inflammation, and antioxidant nutrients: assessing their roles as human papillomavirus cofactors. JNCI Monogr 2003;29–34.
4. HoGY, BurkRD, KleinS, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. JNCI 1995;87:365–371.
5. zur HausenH. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002;2:342–350.
6. TurekLP. The structure, function, and regulation of papillomaviral genes in infection and cervical cancer. Adv Virus Res 1994;44:305–356.
7. FloresER, Allen-HoffmannBL, LeeD, LambertPF. The human papillomavirus type 16 E7 oncogene is required for the productive stage of the viral life cycle. J Virol 2000;74:6622–6631.
8. American Congress of Obstetricians and Gynecologists Committee on Adolescent Health Care. ACOG Committee Opinion No. 301: sexually transmitted diseases in adolescents. Obstet Gynecol 2004;104:891–898.
9. SolomonD, DaveyD, KurmanR, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002;287:2114–2119.
10. FerenczyA, MitaoM, NagaiN, et al. Latent papillomavirus and recurring genital warts. N Engl J Med 1985;313:784–788.
11. ZaakD, HofstetterA, FrimbergerD, SchneedeP. Recurrence of condylomata acuminata of the urethra after conventional and fluorescence-controlled Nd:YAG laser treatment. Urology 2003;61:1011–1015.
12. TingPT, DytocMT. Therapy of external anogenital warts and molluscum contagiosum: a literature review. Dermatol Ther 2004;17:68–101.
13. MawR. Critical appraisal of commonly used treatment for genital warts. Int J STD AIDS 2004;15:357–364.
14. BeutnerKR, SpruanceSL, HoughamAJ, et al. Treatment of genital warts with an immune-response modifier (imiquimod). J Am Acad Dermatol 1998;38:230–239.
15. BeutnerKR, TyringSK, TrofatterKF, Jr., et al. Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts. Antimicrob Agents Chemother 1998;42:789–794.
16. EdwardsL, FerenczyA, EronL, et al. Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Arch Dermatol 1998;134:25–30.
17. SauderDN, SkinnerRB, FoxTL, OwensML. Topical imiquimod 5% cream as an effective treatment for external genital and perianal warts in different patient populations. Sex Transm Dis 2003;30:124–128.
18. EdwardsL. Imiquimod in clinical practice. Australas J Dermatol 1998;39(Suppl 1):S14–S16.
19. GunterJ. Genital and perianal warts: new treatment opportunities for human papillomavirus infection. Am J Obstet Gynecol 2003;189(Suppl):S3–S11.
20. WileyDJ, DouglasJ, BeutnerK, et al. External genital warts: diagnosis, treatment, and prevention. Clin Infect Dis 2002;35(Suppl 2):S210–S224.
21. OstorAG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 1993;12:186–192.
22. MitchellMF, Tortolero-LunaG, WrightT, et al. Cervical human papillomavirus infection and intraepithelial neoplasia: a review. JNCI Monogr 1996;21:17–25.
23. ChangAR. Carcinoma in situ of the cervix and its malignant potential. A lesson from New Zealand. Cytopathology 1990;1:321–328.
24. JakusS, EdmondsP, DuntonC, KingSA. Margin status and excision of cervical intraepithelial neoplasia: a review. Obstet Gynecol Surv 2000;55:520–527.
25. KobakWH, RomanLD, FelixJC, et al. The role of endocervical curettage at cervical conization for high-grade dysplasia. Obstet Gynecol 1995;85:197–201.
26. WidrichT, KennedyAW, MyersTM, et al. Adenocarcinoma in situ of the uterine cervix: management and outcome. Gynecol Oncol 1996;61:304–308.
27. PoynorEA, BarakatRR, HoskinsWJ. Management and follow-up of patients with adenocarcinoma in situ of the uterine cervix. Gynecol Oncol 1995;57:158–164.
28. KoutskyLA, HolmesKK, CritchlowCW, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 1992;327:1272–1278.
29. MoscickiAB, HillsN, ShiboskiS, et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 2001;285:2995–3002.
30. MoscickiAB, ShiboskiS, BroeringJ, et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr 1998;132:277–284.
31. WoodmanCB, CollinsS, WinterH, et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 2001;357:1831–1836.
32. Vail-SmithK, WhiteDM. Risk level, knowledge, and preventive behavior for human papillomaviruses among sexually active college women. J Am Coll Health 1992;40:227–230.
33. RamirezJE, RamosDM, ClaytonL, et al. Genital human papillomavirus infections: knowledge, perception of risk, and actual risk in a nonclinic population of young women. J Womens Health 1997;6:113–121.
34. YacobiE, TennantC, FerranteJ, et al. University students' knowledge and awareness of HPV. Prev Med 1999;28:535–541.
35. DellDL, ChenH, AhmadF, StewartDE. Knowledge about human papillomavirus among adolescents. Obstet Gynecol 2000;96:653–656.
36. GerhardtCA, PongK, KollarLM, et al. Adolescents' knowledge of human papillomavirus and cervical dysplasia. J Pediatr Adolesc Gynecol 2000;13:15–20.
37. HolcombB, BaileyJM, CrawfordK, RuffinMT. Adults' knowledge and behaviors related to human papillomavirus infection. J Am Board Fam Pract 2004;17:16–31.
38. ReedBD, RuffinMT, GorenfloDW, ZazoveP. The psychosexual impact of human papillomavirus cervical infections. J Fam Pract 1999;48:110–116.
39. Centers for Disease Control and Prevention. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR 2010;59:626–629.